Longeveron Inc
LGVN
查看详细走势图
0.558USD
+0.007+1.23%
收盘 12/19, 16:00（美东）报价延迟15分钟
11.75M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.23%
5天
-8.34%
1月
-7.52%
6月
-53.50%
今年开始到现在
-67.75%
1年
-66.18%
查看详细走势图
TradingKey Longeveron Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Longeveron Inc当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名188/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价6.86。中期看，股价处于下降通道。近一个月，市场表现较差，基本面和技术面综合得分也较低。目前股价在压力位和支撑位之间，可以做区间波段操作。
Longeveron Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
3
位分析师
买入
评级
6.862
目标均价
+1057.45%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Longeveron Inc亮点
亮点风险
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
业绩高增长
公司营业收入稳步增长，连续3年增长95.74%
业绩增长期
公司处于发展阶段，最新年度总收入2.39M美元
利润高增长
公司净利润处于行业前列，最新年度总收入2.39M美元
估值合理
公司最新PE估值-0.57，处于3年历史合理位
机构加仓
最新机构持股1.73M股，环比增加35.01%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值505.57K
Longeveron Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Longeveron Inc简介
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
公司代码LGVN
公司Longeveron Inc
CEOPowell (Than)
网址https://www.longeveron.com/
常见问题
Longeveron Inc(LGVN)的当前股价是多少？
Longeveron Inc(LGVN)的当前股价是 0.558。
Longeveron Inc的股票代码是什么？
Longeveron Inc的股票代码是LGVN。
Longeveron Inc股票的52周最高点是多少？
Longeveron Inc股票的52周最高点是2.240。
Longeveron Inc股票的52周最低点是多少？
Longeveron Inc股票的52周最低点是0.533。
Longeveron Inc的市值是多少？
Longeveron Inc的市值是11.75M。
Longeveron Inc的净利润是多少？
Longeveron Inc的净利润为-24.62M。
现在Longeveron Inc(LGVN)的股票是买入、持有还是卖出？
根据分析师评级，Longeveron Inc(LGVN)的总体评级为买入，目标价格为6.862。
Longeveron Inc(LGVN)股票的每股收益（EPS TTM）是多少
Longeveron Inc(LGVN)股票的每股收益（EPS TTM）是-0.974。
相关品种
